deltatrials
Terminated PHASE3 INTERVENTIONAL 3-arm NCT02470585

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (VELIA)

A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Sponsor: AbbVie

Updated 26 times since 2017 Last updated: Oct 2, 2024 Started: Jul 14, 2015 Primary completion: May 3, 2019 Completion: Oct 5, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision not related to patient safety

A PHASE3 clinical study on Ovarian Cancer and Ovarian Neoplasm, this trial is terminated or withdrawn. The trial is conducted by AbbVie and has accumulated 26 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Mar 2017 · 28 days · monthly snapshot~Mar 2017 – ~May 2017 · 2 months · monthly snapshot~May 2017 – ~Aug 2017 · 3 months · monthly snapshot~Aug 2017 – ~Oct 2017 · 2 months · monthly snapshot~Oct 2017 – ~Feb 2018 · 4 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Jul 2019 · 8 months · monthly snapshot~Jul 2019 – ~Oct 2019 · 3 months · monthly snapshot~Oct 2019 – ~Apr 2020 · 6 months · monthly snapshot~Apr 2020 – ~Jun 2020 · 2 months · monthly snapshot~Jun 2020 – ~Oct 2020 · 4 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Aug 2023 · 13 months · monthly snapshot~Aug 2023 – ~Nov 2023 · 3 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Feb 2025 · 3 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

26 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Feb 2025 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Nov 2024 — Feb 2025 [monthly]

    Terminated PHASE3

  4. Sep 2024 — Nov 2024 [monthly]

    Terminated PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

Show 21 earlier versions
  1. Nov 2023 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Active Not RecruitingTerminated

  2. Aug 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Jul 2022 — Aug 2023 [monthly]

    Active Not Recruiting PHASE3

  4. Sep 2021 — Jul 2022 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Oct 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Apr 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

  9. Oct 2019 — Apr 2020 [monthly]

    Active Not Recruiting PHASE3

  10. Jul 2019 — Oct 2019 [monthly]

    Active Not Recruiting PHASE3

  11. Nov 2018 — Jul 2019 [monthly]

    Active Not Recruiting PHASE3

  12. Aug 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  13. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  14. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  15. Feb 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  16. Oct 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE3

  17. Aug 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  18. May 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  19. Mar 2017 — May 2017 [monthly]

    Recruiting PHASE3

  20. Feb 2017 — Mar 2017 [monthly]

    Recruiting PHASE3

  21. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
  • Australia New Zealand Gynaecological Oncology Group
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .